Search
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalAs a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. … Currently under investigation for use in psychotic depression (phase 3 trials).
Mixtures: Mpm Pak, Mpm PakFomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnIt is an antiviral agent that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development
Categories: Compounds used in a research, industrial, or household settingEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalWhen administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration
Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamideAxicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.
Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorLevoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalLevoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal … As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidCalcium citrate
go.drugbank.com/drugs/DB11093ApprovedInvestigationalCalcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.
Mixtures: Citrate De Calcium Plus Vitamine D Et Zinc, Calcium-magnesium With K & Zn and Vitamin D3Categories: Compounds used in a research, industrial, or household settingAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[L7489] Atezolizumab was granted FDA approval on 18 October 2016. … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalthe substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,
Periciazine
go.drugbank.com/drugs/DB01608ApprovedIt also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. … It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.